Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Boadilla Del Monte – page 186

3 267 clinical trials in Boadilla Del Monte, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Boadilla Del Monte at a glance
3 267
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 267 trials in Boadilla Del Monte

Open in trial search

Acute myeloid leukaemia

Not recruiting

Study of Ivosidenib and Azacitidine for Patients Aged 18 and Older with Untreated Acute Myeloid Leukemia with IDH1 Mutation

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Malignant peritoneal neoplasm+2

Not recruiting

Study of Rucaparib and Nivolumab for Maintenance Treatment in Patients with Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer After Chemotherapy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:pharmaand GmbH

Neoplasm

Not recruiting

Study of EOS884448, Dostarlimab, and Inupadenant for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:iTeos Belgium

Diffuse large B-cell lymphoma+1

Not recruiting

Study of Brentuximab Vedotin Combined with R-DHAP Chemotherapy for Patients with Relapsed or Treatment-Resistant CD30-Positive Diffuse Large B-Cell Lymphoma Who Are Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Brentuximab Vedotin
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Lung transplant+1

Not recruiting

Study on the Safety of Allogeneic Mesenchymal Stromal Cells for Patients with Chronic Lung Transplant Rejection

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda

Myelofibrosis+1

Not recruiting

Study of Navtemadlin for Patients with Myelofibrosis Resistant to JAK Inhibitors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Danazol
  • Sponsor:Kartos Therapeutics Inc.

Ovarian low malignant potential tumour

Not recruiting

Study of catequentinib (AL3818) combined with platinum chemotherapy for patients with recurrent or metastatic ovarian, fallopian tube, or primary peritoneal cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Catequentinib Dihydrochloride
  • Sponsor:Advenchen Laboratories LLC

Type 2 diabetes mellitus

Not recruiting

Study on the Effects of AZD5004 and Semaglutide for Adults with Type 2 Diabetes

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Factor VIII deficiency

Not recruiting

Study on Synovial Hypertrophy in Patients with Hemophilia A Using Efanesoctocog Alfa Prophylaxis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Efanesoctocog Alfa
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Skin cancer

Not recruiting

Study of L19IL2 and L19TNF for Patients with Skin Cancer Suitable for Direct Tumor Injection

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Onfekafusp Alfa
  • Sponsor:Philogen S.p.A.

Major depression+1

Not recruiting

Study on Aticaprant and Antidepressant for Preventing Relapse in Adults with Major Depressive Disorder and Anhedonia

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Aticaprant
  • Sponsor:Janssen Cilag International

Squamous cell carcinoma of skin

Not recruiting

Study of Cemiplimab Alone and with RP1 for Patients with Advanced Skin Squamous Cell Carcinoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Replimune Inc.

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Boadilla Del Monte

What the registry says about research in the country

01 Infectious Disease Prevention

Clinical trials focusing on vaccine development and immune responses for multiple infectious diseases, including studies of combination vaccines for childhood diseases and COVID-19 boosters.

  • MMRV Vaccine Studies
  • COVID-19 Booster Research
  • RSV Prevention

Special emphasis on pediatric populations and vaccine co-administration safety protocols.

02 Oncology Research

Comprehensive studies on various cancer types, with focus on pediatric liver cancers and innovative treatment approaches for solid tumors.

  • Hepatoblastoma Treatment
  • High-Grade Glioma Therapy
  • Prostate Cancer Management

Integration of targeted therapies and combination treatment protocols.

03 Cardiovascular Medicine

Investigations into cardiovascular disease prevention and treatment, particularly focusing on post-heart attack care and preventive measures.

  • ASCVD Prevention
  • Acute Coronary Syndrome
  • Cardiovascular Risk Management

Emphasis on long-term cardiovascular outcomes and preventive strategies.

04 Women's Health

Studies examining reproductive health and related conditions, including contraceptive efficacy and treatments for gynecological infections.

  • Contraceptive Development
  • Vaginal Health Studies
  • Treatment of Candidiasis

Focus on innovative delivery systems and treatment options.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.